You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,196,643


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,196,643
Title:Immunostimulatory sequence oligonucleotides and methods of using the same
Abstract: The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.
Inventor(s): Dina; Dino (Oakland, CA), Fearon; Karen L. (Lafayette, CA), Marshall; Jason (Oakland, CA)
Assignee: Dynavax Technologies Corporation (Berkeley, CA)
Application Number:15/232,502
Patent Claims:1. An immunomodulatory polynucleotide, consisting of the sequence of SEQ ID NO:117 or SEQ ID NO:174, wherein the polynucleotide comprises at least one phosphorothioate linkage.

2. The immunomodulatory polynucleotide according to claim 1 wherein the polynucleotide consists of the sequence of SEQ ID NO:117.

3. The immunomodulatory polynucleotide according to claim 1 wherein the polynucleotide consists of the sequence of SEQ ID NO:174.

4. The immunomodulatory polynucleotide according to claim 2 or claim 3, wherein all nucleotide linkages are phosphorothioate linkages.

5. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the immunomodulatory polynucleotide of claim 4.

6. A method of modulating an immune response in a human comprising: administering the pharmaceutical composition of claim 5 to the human in an amount sufficient to modulate an immune response in the human.

7. A method of increasing interferon-gamma (IFN-.gamma.) in a human, comprising: administering the pharmaceutical composition of claim 5 to the human in an amount sufficient to increase IFN-.gamma.in the human.

8. A method of increasing interferon-alpha (IFN-.alpha.) in a human, comprising: administering the pharmaceutical composition of claim 5 to the human in an amount sufficient to increase IFN-.alpha.in the human.

9. The method of claim 6, wherein the human is receiving a prophylactic vaccine or a therapeutic vaccine.

10. The method of claim 9, wherein the therapeutic vaccine comprises tumor associated antigens and/or tumor cells.

11. The method of claim 6, wherein the method further comprises administration of one or more additional therapeutic agents.

12. The method of claim 11, wherein the one or more additional therapeutic agents comprise an anti-tumor antibody, and the anti-tumor antibody is a monoclonal anti-tumor antibody, fragment, or derivative thereof.

13. The method of claim 11, wherein the one or more additional therapeutic agents comprise an immunotherapeutic agent selected from the group consisting of cytokines, adjuvants and antibodies.

14. The method of claim 11, wherein the one or more additional therapeutic agents is selected from the group consisting of anti-tumor antibodies, chemotherapy regimens and radiation treatments.

15. The method of claim 14, wherein the anti-tumor antibodies comprise rituximab or trastuzumab.

16. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the immunomodulatory polynucleotide of claim 2.

17. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the immunomodulatory polynucleotide of claim 3.

Details for Patent 10,196,643

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2022-12-23
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2022-12-23
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2022-12-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.